Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OneMedNet (ONMD) Liabilities and Shareholders Equity (2021 - 2025)

OneMedNet has reported Liabilities and Shareholders Equity over the past 5 years, most recently at $2.2 million for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 42.29% to $2.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.7 million through Dec 2025, down 22.01% year-over-year, with the annual reading at $2.2 million for FY2025, 42.29% down from the prior year.
  • Liabilities and Shareholders Equity was $2.2 million for Q4 2025 at OneMedNet, up from $1.5 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $120.4 million in Q3 2022 and troughed at $464000.0 in Q4 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $3.7 million (2024), against an average of $33.7 million.
  • Year-over-year, Liabilities and Shareholders Equity crashed 98.91% in 2022 and then skyrocketed 703.23% in 2024.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $117.9 million in 2021, then crashed by 98.91% to $1.3 million in 2022, then plummeted by 64.0% to $464000.0 in 2023, then skyrocketed by 703.23% to $3.7 million in 2024, then crashed by 42.29% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for ONMD's Liabilities and Shareholders Equity are $2.2 million (Q4 2025), $1.5 million (Q3 2025), and $2.3 million (Q2 2025).